Assessment of CMV infection in allo-HSCT recipients undergoing LMV prophylaxis by using an implemented diagnostic protocol to identify active viral replication. (PubMed, Antiviral Res) - Feb 22, 2026 - "Letermovir (LMV), a novel antiviral agent targeting the cytomegalovirus (CMV) terminase complex, has significantly changed the management of adult allogenic hematopoietic stem cell transplant (allo-HSCT) recipients...The same result was observed at 200 days post-transplant. These findings confirm that LMV has significantly decreased the incidence of CS-CMVi in CMV seropositive patients and underline the clinical utility of an implemented diagnostic protocol including DNase or RNAemia tests to discriminate between active and abortive CMV infection."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Alessia Cantiani; Enrico Maffini; Eva Caterina Borgatti; Federica Ardizzoia; Federica Lanna; Francesca Bonifazi; Francesco De Felice; Giulia Piccirilli; Liliana Gabrielli; Marcello Roberto; Margherita Ursi; Martina Franceschiello; Martina Tamburello; Michele Dicataldo; Sadia Falcioni; Tiziana Lazzarotto
|